Understanding nano-bio interactions to improve nanocarriers for drug delivery

Ryan M. Pearson, Hao Jui Hsu, Jason Bugno, Seungpyo Hong

Research output: Contribution to journalArticle

30 Citations (Scopus)

Abstract

The ability of cancer-targeted nanoparticles (NPs) to reach their site of action and evoke a desired biological response after intravenous injection is critical to achieve clinically significant in vivo efficacy. Throughout their journey in the body, NPs must successfully traverse biological environments such as blood circulation and tumor microenvironments. The interactions that occur at the interface between NPs and biological components are complex, requiring a thorough understanding of the nano-bio interactions to design NPs with maximal therapeutic indices. In this article, we review the challenges presented by the multiscale, important biocompartments that NPs face, describe the crucial nano-bio interactions present at each stage, and discuss potential strategies to overcome those challenges. This review suggests design considerations for NPs to optimally modulate their physicochemical properties to achieve desired biological responses, which are expected to aid chemists, engineers, and clinical scientists to design and develop highly effective delivery platforms for cancer therapy.

Original languageEnglish
Pages (from-to)227-237
Number of pages11
JournalMRS Bulletin
Volume39
Issue number3
DOIs
Publication statusPublished - 2014 Mar 1

Fingerprint

Drug delivery
delivery
drugs
Nanoparticles
nanoparticles
interactions
cancer
blood circulation
Hemodynamics
engineers
Tumors
therapy
tumors
platforms
injection
Engineers

All Science Journal Classification (ASJC) codes

  • Materials Science(all)
  • Condensed Matter Physics
  • Physical and Theoretical Chemistry

Cite this

Pearson, Ryan M. ; Hsu, Hao Jui ; Bugno, Jason ; Hong, Seungpyo. / Understanding nano-bio interactions to improve nanocarriers for drug delivery. In: MRS Bulletin. 2014 ; Vol. 39, No. 3. pp. 227-237.
@article{9748a95214eb49aaa188370d410a3313,
title = "Understanding nano-bio interactions to improve nanocarriers for drug delivery",
abstract = "The ability of cancer-targeted nanoparticles (NPs) to reach their site of action and evoke a desired biological response after intravenous injection is critical to achieve clinically significant in vivo efficacy. Throughout their journey in the body, NPs must successfully traverse biological environments such as blood circulation and tumor microenvironments. The interactions that occur at the interface between NPs and biological components are complex, requiring a thorough understanding of the nano-bio interactions to design NPs with maximal therapeutic indices. In this article, we review the challenges presented by the multiscale, important biocompartments that NPs face, describe the crucial nano-bio interactions present at each stage, and discuss potential strategies to overcome those challenges. This review suggests design considerations for NPs to optimally modulate their physicochemical properties to achieve desired biological responses, which are expected to aid chemists, engineers, and clinical scientists to design and develop highly effective delivery platforms for cancer therapy.",
author = "Pearson, {Ryan M.} and Hsu, {Hao Jui} and Jason Bugno and Seungpyo Hong",
year = "2014",
month = "3",
day = "1",
doi = "10.1557/mrs.2014.9",
language = "English",
volume = "39",
pages = "227--237",
journal = "MRS Bulletin",
issn = "0883-7694",
publisher = "Materials Research Society",
number = "3",

}

Understanding nano-bio interactions to improve nanocarriers for drug delivery. / Pearson, Ryan M.; Hsu, Hao Jui; Bugno, Jason; Hong, Seungpyo.

In: MRS Bulletin, Vol. 39, No. 3, 01.03.2014, p. 227-237.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Understanding nano-bio interactions to improve nanocarriers for drug delivery

AU - Pearson, Ryan M.

AU - Hsu, Hao Jui

AU - Bugno, Jason

AU - Hong, Seungpyo

PY - 2014/3/1

Y1 - 2014/3/1

N2 - The ability of cancer-targeted nanoparticles (NPs) to reach their site of action and evoke a desired biological response after intravenous injection is critical to achieve clinically significant in vivo efficacy. Throughout their journey in the body, NPs must successfully traverse biological environments such as blood circulation and tumor microenvironments. The interactions that occur at the interface between NPs and biological components are complex, requiring a thorough understanding of the nano-bio interactions to design NPs with maximal therapeutic indices. In this article, we review the challenges presented by the multiscale, important biocompartments that NPs face, describe the crucial nano-bio interactions present at each stage, and discuss potential strategies to overcome those challenges. This review suggests design considerations for NPs to optimally modulate their physicochemical properties to achieve desired biological responses, which are expected to aid chemists, engineers, and clinical scientists to design and develop highly effective delivery platforms for cancer therapy.

AB - The ability of cancer-targeted nanoparticles (NPs) to reach their site of action and evoke a desired biological response after intravenous injection is critical to achieve clinically significant in vivo efficacy. Throughout their journey in the body, NPs must successfully traverse biological environments such as blood circulation and tumor microenvironments. The interactions that occur at the interface between NPs and biological components are complex, requiring a thorough understanding of the nano-bio interactions to design NPs with maximal therapeutic indices. In this article, we review the challenges presented by the multiscale, important biocompartments that NPs face, describe the crucial nano-bio interactions present at each stage, and discuss potential strategies to overcome those challenges. This review suggests design considerations for NPs to optimally modulate their physicochemical properties to achieve desired biological responses, which are expected to aid chemists, engineers, and clinical scientists to design and develop highly effective delivery platforms for cancer therapy.

UR - http://www.scopus.com/inward/record.url?scp=84910684199&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84910684199&partnerID=8YFLogxK

U2 - 10.1557/mrs.2014.9

DO - 10.1557/mrs.2014.9

M3 - Article

AN - SCOPUS:84910684199

VL - 39

SP - 227

EP - 237

JO - MRS Bulletin

JF - MRS Bulletin

SN - 0883-7694

IS - 3

ER -